申请人:BAYER PHARMA AG
公开号:WO2018172250A1
公开(公告)日:2018-09-27
The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.
本发明描述了一般式(I)的2-甲基喹唑啉化合物,制备该化合物的方法,用于制备该化合物的中间体化合物,包含该化合物的药物组合物和组合物,以及用于制造药物组合物的该化合物的用途。一般式(I)的2-甲基取代喹唑啉化合物有效且选择性地抑制Ras-Sos相互作用,而不显著靶向EGFR受体。因此,它们对于治疗或预防疾病特别是高增殖性疾病,如癌症作为单一药剂或与其他活性成分组合使用是有用的。